DNA-based vaccine clears nearly half of precancerous cervical lesions in clinical trial

DNA-based vaccine clears nearly half of precancerous cervical lesions in clinical trialUsing a novel synthetic platform for creating vaccines originally developed in the laboratory of David Weiner, PhD, a professor of Pathology and Laboratory Medicine from the Perelman School of Medicine at the University of Pennsylvania, a team led by his colleagues at the Johns Hopkins University School of Medicine, has successfully eradicated precancerous cervical lesions in nearly half of the women who received the investigational vaccine in a clinical trial.

Embedly Powered